nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—TYMS—head and neck cancer	0.194	1	CbGaD
Methotrexate—esophageal cancer—head and neck cancer	0.117	0.278	CtDrD
Methotrexate—bone cancer—head and neck cancer	0.0841	0.199	CtDrD
Methotrexate—stomach cancer—head and neck cancer	0.0796	0.189	CtDrD
Methotrexate—muscle cancer—head and neck cancer	0.0743	0.176	CtDrD
Methotrexate—germ cell cancer—head and neck cancer	0.0667	0.158	CtDrD
Methotrexate—MTHFR—Fluorouracil—head and neck cancer	0.0467	0.184	CbGbCtD
Methotrexate—TYMS—Fluorouracil—head and neck cancer	0.0398	0.157	CbGbCtD
Methotrexate—ABCC10—Docetaxel—head and neck cancer	0.0251	0.0988	CbGbCtD
Methotrexate—ABCC3—Fluorouracil—head and neck cancer	0.0206	0.0813	CbGbCtD
Methotrexate—SLC22A7—Fluorouracil—head and neck cancer	0.0161	0.0636	CbGbCtD
Methotrexate—ABCC4—Fluorouracil—head and neck cancer	0.0158	0.0621	CbGbCtD
Methotrexate—SLCO1B3—Docetaxel—head and neck cancer	0.014	0.0552	CbGbCtD
Methotrexate—SLC22A7—Docetaxel—head and neck cancer	0.0123	0.0486	CbGbCtD
Methotrexate—ABCC1—Vinblastine—head and neck cancer	0.0117	0.0463	CbGbCtD
Methotrexate—ABCC1—Docetaxel—head and neck cancer	0.00968	0.0381	CbGbCtD
Methotrexate—ABCC2—Vinblastine—head and neck cancer	0.00869	0.0342	CbGbCtD
Methotrexate—ABCG2—Fluorouracil—head and neck cancer	0.00848	0.0334	CbGbCtD
Methotrexate—ABCC2—Docetaxel—head and neck cancer	0.00716	0.0282	CbGbCtD
Methotrexate—ABCG2—Docetaxel—head and neck cancer	0.00648	0.0255	CbGbCtD
Methotrexate—ALB—Fluorouracil—head and neck cancer	0.00585	0.023	CbGbCtD
Methotrexate—ABCB1—Vinblastine—head and neck cancer	0.00283	0.0112	CbGbCtD
Methotrexate—ABCB1—Docetaxel—head and neck cancer	0.00234	0.0092	CbGbCtD
Methotrexate—FOLR1—exocrine gland—head and neck cancer	0.00123	0.0493	CbGeAlD
Methotrexate—SLC19A1—tongue—head and neck cancer	0.0012	0.0481	CbGeAlD
Methotrexate—FOLR1—mouth—head and neck cancer	0.000922	0.0369	CbGeAlD
Methotrexate—SLC19A1—mouth—head and neck cancer	0.000809	0.0324	CbGeAlD
Methotrexate—Raltitrexed—TYMS—head and neck cancer	0.000797	0.32	CrCbGaD
Methotrexate—GGH—hair follicle—head and neck cancer	0.000781	0.0312	CbGeAlD
Methotrexate—FOLR1—parotid gland—head and neck cancer	0.000642	0.0257	CbGeAlD
Methotrexate—FOLR1—saliva-secreting gland—head and neck cancer	0.000615	0.0246	CbGeAlD
Methotrexate—Leucovorin—TYMS—head and neck cancer	0.000604	0.243	CrCbGaD
Methotrexate—Pralatrexate—TYMS—head and neck cancer	0.000604	0.243	CrCbGaD
Methotrexate—FOLR1—epithelium—head and neck cancer	0.000536	0.0215	CbGeAlD
Methotrexate—Pemetrexed—TYMS—head and neck cancer	0.000483	0.194	CrCbGaD
Methotrexate—TYMS—Paclitaxel—Docetaxel—head and neck cancer	0.000477	0.456	CbGdCrCtD
Methotrexate—FOLR1—trachea—head and neck cancer	0.000474	0.019	CbGeAlD
Methotrexate—GGH—parotid gland—head and neck cancer	0.000427	0.0171	CbGeAlD
Methotrexate—FOLR1—lymphoid tissue—head and neck cancer	0.000413	0.0165	CbGeAlD
Methotrexate—GGH—saliva-secreting gland—head and neck cancer	0.000409	0.0164	CbGeAlD
Methotrexate—SLCO4C1—parotid gland—head and neck cancer	0.000378	0.0151	CbGeAlD
Methotrexate—FOLR1—thyroid gland—head and neck cancer	0.000375	0.015	CbGeAlD
Methotrexate—SLC19A1—lymphoid tissue—head and neck cancer	0.000362	0.0145	CbGeAlD
Methotrexate—FPGS—saliva-secreting gland—head and neck cancer	0.000359	0.0144	CbGeAlD
Methotrexate—FOLR1—head—head and neck cancer	0.000333	0.0133	CbGeAlD
Methotrexate—MTHFR—neck—head and neck cancer	0.000331	0.0132	CbGeAlD
Methotrexate—FPGS—connective tissue—head and neck cancer	0.00033	0.0132	CbGeAlD
Methotrexate—SLC19A1—thyroid gland—head and neck cancer	0.000329	0.0132	CbGeAlD
Methotrexate—ATIC—connective tissue—head and neck cancer	0.000319	0.0128	CbGeAlD
Methotrexate—GGH—trachea—head and neck cancer	0.000315	0.0126	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vinblastine—head and neck cancer	0.000307	0.293	CbGdCrCtD
Methotrexate—ATIC—epithelium—head and neck cancer	0.000303	0.0121	CbGeAlD
Methotrexate—SLC19A1—head—head and neck cancer	0.000292	0.0117	CbGeAlD
Methotrexate—PGD—neck—head and neck cancer	0.000288	0.0115	CbGeAlD
Methotrexate—SLCO4C1—trachea—head and neck cancer	0.00028	0.0112	CbGeAlD
Methotrexate—SLC46A1—lymphoid tissue—head and neck cancer	0.000279	0.0112	CbGeAlD
Methotrexate—FPGS—trachea—head and neck cancer	0.000277	0.0111	CbGeAlD
Methotrexate—TYMS—Vincristine—Vinblastine—head and neck cancer	0.000262	0.251	CbGdCrCtD
Methotrexate—ABCC1—hair follicle—head and neck cancer	0.00026	0.0104	CbGeAlD
Methotrexate—SLC46A1—thyroid gland—head and neck cancer	0.000253	0.0101	CbGeAlD
Methotrexate—GGH—thyroid gland—head and neck cancer	0.000249	0.00998	CbGeAlD
Methotrexate—FPGS—lymphoid tissue—head and neck cancer	0.000241	0.00966	CbGeAlD
Methotrexate—PGD—parotid gland—head and neck cancer	0.000234	0.00937	CbGeAlD
Methotrexate—ATIC—lymphoid tissue—head and neck cancer	0.000233	0.00934	CbGeAlD
Methotrexate—DHFR—saliva-secreting gland—head and neck cancer	0.000233	0.00934	CbGeAlD
Methotrexate—SLC46A1—head—head and neck cancer	0.000225	0.009	CbGeAlD
Methotrexate—PGD—saliva-secreting gland—head and neck cancer	0.000224	0.00898	CbGeAlD
Methotrexate—GGH—head—head and neck cancer	0.000221	0.00885	CbGeAlD
Methotrexate—FPGS—thyroid gland—head and neck cancer	0.000219	0.00877	CbGeAlD
Methotrexate—Neoplasm—Hydroxyurea—head and neck cancer	0.000219	0.00346	CcSEcCtD
Methotrexate—TYMS—connective tissue—head and neck cancer	0.000217	0.00866	CbGeAlD
Methotrexate—Pulmonary oedema—Hydroxyurea—head and neck cancer	0.000216	0.00341	CcSEcCtD
Methotrexate—DHFR—connective tissue—head and neck cancer	0.000214	0.00858	CbGeAlD
Methotrexate—ATIC—thyroid gland—head and neck cancer	0.000212	0.00848	CbGeAlD
Methotrexate—Skin hyperpigmentation—Docetaxel—head and neck cancer	0.000211	0.00334	CcSEcCtD
Methotrexate—Febrile neutropenia—Docetaxel—head and neck cancer	0.000209	0.00331	CcSEcCtD
Methotrexate—Polyp—Docetaxel—head and neck cancer	0.000207	0.00327	CcSEcCtD
Methotrexate—Deep vein thrombosis—Docetaxel—head and neck cancer	0.000207	0.00327	CcSEcCtD
Methotrexate—PGD—connective tissue—head and neck cancer	0.000206	0.00825	CbGeAlD
Methotrexate—Eruption—Docetaxel—head and neck cancer	0.000204	0.00323	CcSEcCtD
Methotrexate—SLC19A1—lymph node—head and neck cancer	0.000204	0.00818	CbGeAlD
Methotrexate—Speech disorder—Fluorouracil—head and neck cancer	0.000203	0.0032	CcSEcCtD
Methotrexate—ABCC10—parotid gland—head and neck cancer	0.000201	0.00804	CbGeAlD
Methotrexate—Extravasation—Fluorouracil—head and neck cancer	0.0002	0.00316	CcSEcCtD
Methotrexate—Cerebrovascular accident—Vinblastine—head and neck cancer	0.000197	0.00311	CcSEcCtD
Methotrexate—Embolism—Docetaxel—head and neck cancer	0.000196	0.0031	CcSEcCtD
Methotrexate—Hepatic failure—Hydroxyurea—head and neck cancer	0.000196	0.00309	CcSEcCtD
Methotrexate—FPGS—head—head and neck cancer	0.000194	0.00778	CbGeAlD
Methotrexate—Nail disorder—Docetaxel—head and neck cancer	0.000194	0.00307	CcSEcCtD
Methotrexate—ABCC10—saliva-secreting gland—head and neck cancer	0.000192	0.0077	CbGeAlD
Methotrexate—Renal failure acute—Hydroxyurea—head and neck cancer	0.00019	0.00301	CcSEcCtD
Methotrexate—Herpes simplex—Fluorouracil—head and neck cancer	0.000189	0.00299	CcSEcCtD
Methotrexate—Cyst—Docetaxel—head and neck cancer	0.000188	0.00298	CcSEcCtD
Methotrexate—ATIC—head—head and neck cancer	0.000188	0.00753	CbGeAlD
Methotrexate—Liver disorder—Docetaxel—head and neck cancer	0.000185	0.00292	CcSEcCtD
Methotrexate—Dysarthria—Fluorouracil—head and neck cancer	0.000184	0.00291	CcSEcCtD
Methotrexate—Ulcer—Fluorouracil—head and neck cancer	0.000184	0.00291	CcSEcCtD
Methotrexate—SLC16A1—epithelium—head and neck cancer	0.000183	0.00731	CbGeAlD
Methotrexate—Burning sensation—Docetaxel—head and neck cancer	0.000181	0.00286	CcSEcCtD
Methotrexate—DHFR—trachea—head and neck cancer	0.00018	0.0072	CbGeAlD
Methotrexate—Inflammation—Fluorouracil—head and neck cancer	0.00018	0.00284	CcSEcCtD
Methotrexate—Interstitial lung disease—Docetaxel—head and neck cancer	0.000178	0.00281	CcSEcCtD
Methotrexate—SLCO1C1—thyroid gland—head and neck cancer	0.000176	0.00705	CbGeAlD
Methotrexate—MTHFR—lymphoid tissue—head and neck cancer	0.000173	0.00694	CbGeAlD
Methotrexate—PGD—trachea—head and neck cancer	0.000173	0.00692	CbGeAlD
Methotrexate—Pleural effusion—Docetaxel—head and neck cancer	0.000164	0.0026	CcSEcCtD
Methotrexate—Hepatotoxicity—Docetaxel—head and neck cancer	0.000163	0.00258	CcSEcCtD
Methotrexate—Necrosis—Docetaxel—head and neck cancer	0.00016	0.00253	CcSEcCtD
Methotrexate—Coma—Fluorouracil—head and neck cancer	0.000159	0.00252	CcSEcCtD
Methotrexate—Breast disorder—Hydroxyurea—head and neck cancer	0.000159	0.00251	CcSEcCtD
Methotrexate—TYMS—lymphoid tissue—head and neck cancer	0.000158	0.00634	CbGeAlD
Methotrexate—Pancytopenia—Vinblastine—head and neck cancer	0.000158	0.0025	CcSEcCtD
Methotrexate—MTHFR—thyroid gland—head and neck cancer	0.000158	0.00631	CbGeAlD
Methotrexate—SLC46A1—lymph node—head and neck cancer	0.000157	0.0063	CbGeAlD
Methotrexate—DHFR—lymphoid tissue—head and neck cancer	0.000157	0.00627	CbGeAlD
Methotrexate—SLCO1C1—head—head and neck cancer	0.000156	0.00626	CbGeAlD
Methotrexate—SLCO3A1—thyroid gland—head and neck cancer	0.000155	0.0062	CbGeAlD
Methotrexate—GGH—lymph node—head and neck cancer	0.000155	0.0062	CbGeAlD
Methotrexate—AOX1—trachea—head and neck cancer	0.000152	0.0061	CbGeAlD
Methotrexate—Sepsis—Fluorouracil—head and neck cancer	0.000151	0.00239	CcSEcCtD
Methotrexate—PGD—lymphoid tissue—head and neck cancer	0.000151	0.00603	CbGeAlD
Methotrexate—Pancreatitis—Hydroxyurea—head and neck cancer	0.000149	0.00236	CcSEcCtD
Methotrexate—ABCC10—trachea—head and neck cancer	0.000148	0.00594	CbGeAlD
Methotrexate—Depression—Vinblastine—head and neck cancer	0.000148	0.00234	CcSEcCtD
Methotrexate—Thrombophlebitis—Fluorouracil—head and neck cancer	0.000146	0.00231	CcSEcCtD
Methotrexate—Pancytopenia—Hydroxyurea—head and neck cancer	0.000144	0.00228	CcSEcCtD
Methotrexate—Extravasation—Docetaxel—head and neck cancer	0.000144	0.00228	CcSEcCtD
Methotrexate—Photosensitivity—Fluorouracil—head and neck cancer	0.000144	0.00228	CcSEcCtD
Methotrexate—TYMS—thyroid gland—head and neck cancer	0.000144	0.00575	CbGeAlD
Methotrexate—DHFR—thyroid gland—head and neck cancer	0.000142	0.0057	CbGeAlD
Methotrexate—Dysuria—Hydroxyurea—head and neck cancer	0.000142	0.00225	CcSEcCtD
Methotrexate—Neutropenia—Hydroxyurea—head and neck cancer	0.000142	0.00225	CcSEcCtD
Methotrexate—ABCC1—parotid gland—head and neck cancer	0.000142	0.00568	CbGeAlD
Methotrexate—MTHFR—head—head and neck cancer	0.00014	0.00559	CbGeAlD
Methotrexate—Bone disorder—Docetaxel—head and neck cancer	0.000139	0.0022	CcSEcCtD
Methotrexate—Agranulocytosis—Vinblastine—head and neck cancer	0.000139	0.00219	CcSEcCtD
Methotrexate—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.000138	0.00219	CcSEcCtD
Methotrexate—SLCO3A1—head—head and neck cancer	0.000138	0.0055	CbGeAlD
Methotrexate—PGD—thyroid gland—head and neck cancer	0.000137	0.00548	CbGeAlD
Methotrexate—Oliguria—Docetaxel—head and neck cancer	0.000136	0.00216	CcSEcCtD
Methotrexate—FPGS—lymph node—head and neck cancer	0.000136	0.00545	CbGeAlD
Methotrexate—Infestation NOS—Hydroxyurea—head and neck cancer	0.000135	0.00214	CcSEcCtD
Methotrexate—Infestation—Hydroxyurea—head and neck cancer	0.000135	0.00214	CcSEcCtD
Methotrexate—Drowsiness—Hydroxyurea—head and neck cancer	0.000135	0.00214	CcSEcCtD
Methotrexate—Haemoglobin—Vinblastine—head and neck cancer	0.000134	0.00212	CcSEcCtD
Methotrexate—Haemorrhage—Vinblastine—head and neck cancer	0.000133	0.00211	CcSEcCtD
Methotrexate—Pharyngitis—Vinblastine—head and neck cancer	0.000132	0.00209	CcSEcCtD
Methotrexate—Stomatitis—Hydroxyurea—head and neck cancer	0.000132	0.00209	CcSEcCtD
Methotrexate—ATIC—lymph node—head and neck cancer	0.000132	0.00527	CbGeAlD
Methotrexate—Inflammation—Docetaxel—head and neck cancer	0.00013	0.00205	CcSEcCtD
Methotrexate—ABCC10—lymphoid tissue—head and neck cancer	0.000129	0.00517	CbGeAlD
Methotrexate—Lethargy—Fluorouracil—head and neck cancer	0.000129	0.00204	CcSEcCtD
Methotrexate—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000128	0.00203	CcSEcCtD
Methotrexate—Respiratory failure—Docetaxel—head and neck cancer	0.000128	0.00203	CcSEcCtD
Methotrexate—SLC16A1—thyroid gland—head and neck cancer	0.000128	0.00511	CbGeAlD
Methotrexate—TYMS—head—head and neck cancer	0.000128	0.0051	CbGeAlD
Methotrexate—Osteoarthritis—Fluorouracil—head and neck cancer	0.000127	0.002	CcSEcCtD
Methotrexate—DHFR—head—head and neck cancer	0.000126	0.00505	CbGeAlD
Methotrexate—Pulmonary embolism—Docetaxel—head and neck cancer	0.000126	0.00199	CcSEcCtD
Methotrexate—Haemoglobin—Hydroxyurea—head and neck cancer	0.000122	0.00193	CcSEcCtD
Methotrexate—Haemorrhage—Hydroxyurea—head and neck cancer	0.000122	0.00192	CcSEcCtD
Methotrexate—PGD—head—head and neck cancer	0.000121	0.00486	CbGeAlD
Methotrexate—Irritability—Fluorouracil—head and neck cancer	0.000121	0.00191	CcSEcCtD
Methotrexate—AOX1—thyroid gland—head and neck cancer	0.000121	0.00483	CbGeAlD
Methotrexate—Skin exfoliation—Docetaxel—head and neck cancer	0.00012	0.0019	CcSEcCtD
Methotrexate—Ataxia—Fluorouracil—head and neck cancer	0.000119	0.00188	CcSEcCtD
Methotrexate—ABCC3—thyroid gland—head and neck cancer	0.000118	0.00472	CbGeAlD
Methotrexate—Alopecia—Vinblastine—head and neck cancer	0.000118	0.00186	CcSEcCtD
Methotrexate—ABCG2—parotid gland—head and neck cancer	0.000118	0.00471	CbGeAlD
Methotrexate—ABCC10—thyroid gland—head and neck cancer	0.000117	0.0047	CbGeAlD
Methotrexate—Neoplasm—Docetaxel—head and neck cancer	0.000114	0.0018	CcSEcCtD
Methotrexate—SLC16A1—head—head and neck cancer	0.000113	0.00454	CbGeAlD
Methotrexate—ABCG2—saliva-secreting gland—head and neck cancer	0.000113	0.00451	CbGeAlD
Methotrexate—Pulmonary oedema—Docetaxel—head and neck cancer	0.000112	0.00177	CcSEcCtD
Methotrexate—Angiopathy—Hydroxyurea—head and neck cancer	0.00011	0.00174	CcSEcCtD
Methotrexate—SLCO1C1—lymph node—head and neck cancer	0.00011	0.00438	CbGeAlD
Methotrexate—Sepsis—Docetaxel—head and neck cancer	0.000109	0.00173	CcSEcCtD
Methotrexate—Chills—Hydroxyurea—head and neck cancer	0.000109	0.00173	CcSEcCtD
Methotrexate—Eosinophilia—Fluorouracil—head and neck cancer	0.000108	0.00171	CcSEcCtD
Methotrexate—Ill-defined disorder—Vinblastine—head and neck cancer	0.000108	0.0017	CcSEcCtD
Methotrexate—Alopecia—Hydroxyurea—head and neck cancer	0.000107	0.0017	CcSEcCtD
Methotrexate—Anaemia—Vinblastine—head and neck cancer	0.000107	0.0017	CcSEcCtD
Methotrexate—Erythema—Hydroxyurea—head and neck cancer	0.000106	0.00167	CcSEcCtD
Methotrexate—Thrombophlebitis—Docetaxel—head and neck cancer	0.000105	0.00167	CcSEcCtD
Methotrexate—ABCC1—trachea—head and neck cancer	0.000105	0.0042	CbGeAlD
Methotrexate—Malaise—Vinblastine—head and neck cancer	0.000105	0.00166	CcSEcCtD
Methotrexate—ABCC3—head—head and neck cancer	0.000105	0.00419	CbGeAlD
Methotrexate—Vertigo—Vinblastine—head and neck cancer	0.000104	0.00165	CcSEcCtD
Methotrexate—Leukopenia—Vinblastine—head and neck cancer	0.000104	0.00164	CcSEcCtD
Methotrexate—Pancytopenia—Fluorouracil—head and neck cancer	0.000104	0.00164	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000102	0.00161	CcSEcCtD
Methotrexate—Hepatic failure—Docetaxel—head and neck cancer	0.000102	0.00161	CcSEcCtD
Methotrexate—Convulsion—Vinblastine—head and neck cancer	0.000101	0.00159	CcSEcCtD
Methotrexate—Photosensitivity reaction—Fluorouracil—head and neck cancer	9.98e-05	0.00158	CcSEcCtD
Methotrexate—Ill-defined disorder—Hydroxyurea—head and neck cancer	9.82e-05	0.00155	CcSEcCtD
Methotrexate—Pneumonia—Fluorouracil—head and neck cancer	9.81e-05	0.00155	CcSEcCtD
Methotrexate—MTHFR—lymph node—head and neck cancer	9.79e-05	0.00392	CbGeAlD
Methotrexate—Anaemia—Hydroxyurea—head and neck cancer	9.78e-05	0.00155	CcSEcCtD
Methotrexate—Discomfort—Vinblastine—head and neck cancer	9.76e-05	0.00154	CcSEcCtD
Methotrexate—Infestation NOS—Fluorouracil—head and neck cancer	9.75e-05	0.00154	CcSEcCtD
Methotrexate—Infestation—Fluorouracil—head and neck cancer	9.75e-05	0.00154	CcSEcCtD
Methotrexate—ABCC4—thyroid gland—head and neck cancer	9.74e-05	0.0039	CbGeAlD
Methotrexate—Visual disturbance—Docetaxel—head and neck cancer	9.63e-05	0.00152	CcSEcCtD
Methotrexate—SLCO3A1—lymph node—head and neck cancer	9.63e-05	0.00385	CbGeAlD
Methotrexate—Malaise—Hydroxyurea—head and neck cancer	9.54e-05	0.00151	CcSEcCtD
Methotrexate—Stomatitis—Fluorouracil—head and neck cancer	9.5e-05	0.0015	CcSEcCtD
Methotrexate—Conjunctivitis—Fluorouracil—head and neck cancer	9.48e-05	0.0015	CcSEcCtD
Methotrexate—Leukopenia—Hydroxyurea—head and neck cancer	9.47e-05	0.0015	CcSEcCtD
Methotrexate—Lethargy—Docetaxel—head and neck cancer	9.32e-05	0.00147	CcSEcCtD
Methotrexate—Thrombocytopenia—Vinblastine—head and neck cancer	9.27e-05	0.00147	CcSEcCtD
Methotrexate—Epistaxis—Fluorouracil—head and neck cancer	9.2e-05	0.00145	CcSEcCtD
Methotrexate—Convulsion—Hydroxyurea—head and neck cancer	9.17e-05	0.00145	CcSEcCtD
Methotrexate—Agranulocytosis—Fluorouracil—head and neck cancer	9.1e-05	0.00144	CcSEcCtD
Methotrexate—Anorexia—Vinblastine—head and neck cancer	9.03e-05	0.00143	CcSEcCtD
Methotrexate—SLCO1A2—head—head and neck cancer	8.97e-05	0.00359	CbGeAlD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	8.95e-05	0.00142	CcSEcCtD
Methotrexate—TYMS—lymph node—head and neck cancer	8.93e-05	0.00357	CbGeAlD
Methotrexate—Discomfort—Hydroxyurea—head and neck cancer	8.9e-05	0.00141	CcSEcCtD
Methotrexate—DHFR—lymph node—head and neck cancer	8.84e-05	0.00354	CbGeAlD
Methotrexate—Haemoglobin—Fluorouracil—head and neck cancer	8.8e-05	0.00139	CcSEcCtD
Methotrexate—Haemorrhage—Fluorouracil—head and neck cancer	8.75e-05	0.00138	CcSEcCtD
Methotrexate—Pharyngitis—Fluorouracil—head and neck cancer	8.69e-05	0.00137	CcSEcCtD
Methotrexate—ABCC4—head—head and neck cancer	8.64e-05	0.00346	CbGeAlD
Methotrexate—Ataxia—Docetaxel—head and neck cancer	8.59e-05	0.00136	CcSEcCtD
Methotrexate—Infection—Hydroxyurea—head and neck cancer	8.58e-05	0.00136	CcSEcCtD
Methotrexate—SLC22A8—head—head and neck cancer	8.57e-05	0.00343	CbGeAlD
Methotrexate—Paraesthesia—Vinblastine—head and neck cancer	8.51e-05	0.00134	CcSEcCtD
Methotrexate—PGD—lymph node—head and neck cancer	8.5e-05	0.0034	CbGeAlD
Methotrexate—Nervous system disorder—Hydroxyurea—head and neck cancer	8.47e-05	0.00134	CcSEcCtD
Methotrexate—Thrombocytopenia—Hydroxyurea—head and neck cancer	8.46e-05	0.00134	CcSEcCtD
Methotrexate—Liver function test abnormal—Docetaxel—head and neck cancer	8.43e-05	0.00133	CcSEcCtD
Methotrexate—Skin disorder—Hydroxyurea—head and neck cancer	8.39e-05	0.00133	CcSEcCtD
Methotrexate—ABCC1—thyroid gland—head and neck cancer	8.3e-05	0.00332	CbGeAlD
Methotrexate—Breast disorder—Docetaxel—head and neck cancer	8.25e-05	0.0013	CcSEcCtD
Methotrexate—Anorexia—Hydroxyurea—head and neck cancer	8.23e-05	0.0013	CcSEcCtD
Methotrexate—Decreased appetite—Vinblastine—head and neck cancer	8.23e-05	0.0013	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	8.22e-05	0.0013	CcSEcCtD
Methotrexate—Pain—Vinblastine—head and neck cancer	8.1e-05	0.00128	CcSEcCtD
Methotrexate—SLC16A1—lymph node—head and neck cancer	7.94e-05	0.00318	CbGeAlD
Methotrexate—Feeling abnormal—Vinblastine—head and neck cancer	7.81e-05	0.00123	CcSEcCtD
Methotrexate—Gastrointestinal pain—Vinblastine—head and neck cancer	7.75e-05	0.00122	CcSEcCtD
Methotrexate—Alopecia—Fluorouracil—head and neck cancer	7.73e-05	0.00122	CcSEcCtD
Methotrexate—Dyspnoea—Hydroxyurea—head and neck cancer	7.7e-05	0.00122	CcSEcCtD
Methotrexate—Somnolence—Hydroxyurea—head and neck cancer	7.68e-05	0.00121	CcSEcCtD
Methotrexate—Erythema—Fluorouracil—head and neck cancer	7.62e-05	0.0012	CcSEcCtD
Methotrexate—Dyspepsia—Hydroxyurea—head and neck cancer	7.6e-05	0.0012	CcSEcCtD
Methotrexate—Decreased appetite—Hydroxyurea—head and neck cancer	7.51e-05	0.00119	CcSEcCtD
Methotrexate—Pancytopenia—Docetaxel—head and neck cancer	7.49e-05	0.00119	CcSEcCtD
Methotrexate—AOX1—lymph node—head and neck cancer	7.49e-05	0.003	CbGeAlD
Methotrexate—Abdominal pain—Vinblastine—head and neck cancer	7.49e-05	0.00118	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	7.46e-05	0.00118	CcSEcCtD
Methotrexate—Fatigue—Hydroxyurea—head and neck cancer	7.45e-05	0.00118	CcSEcCtD
Methotrexate—Pain—Hydroxyurea—head and neck cancer	7.39e-05	0.00117	CcSEcCtD
Methotrexate—Neutropenia—Docetaxel—head and neck cancer	7.38e-05	0.00117	CcSEcCtD
Methotrexate—ABCC3—lymph node—head and neck cancer	7.33e-05	0.00293	CbGeAlD
Methotrexate—ABCC10—lymph node—head and neck cancer	7.29e-05	0.00292	CbGeAlD
Methotrexate—Vision blurred—Fluorouracil—head and neck cancer	7.18e-05	0.00114	CcSEcCtD
Methotrexate—Feeling abnormal—Hydroxyurea—head and neck cancer	7.12e-05	0.00113	CcSEcCtD
Methotrexate—Pneumonia—Docetaxel—head and neck cancer	7.08e-05	0.00112	CcSEcCtD
Methotrexate—Anaemia—Fluorouracil—head and neck cancer	7.04e-05	0.00111	CcSEcCtD
Methotrexate—Infestation NOS—Docetaxel—head and neck cancer	7.04e-05	0.00111	CcSEcCtD
Methotrexate—Infestation—Docetaxel—head and neck cancer	7.04e-05	0.00111	CcSEcCtD
Methotrexate—Hypersensitivity—Vinblastine—head and neck cancer	6.98e-05	0.0011	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	6.98e-05	0.0011	CcSEcCtD
Methotrexate—Renal failure—Docetaxel—head and neck cancer	6.92e-05	0.00109	CcSEcCtD
Methotrexate—ABCG2—thyroid gland—head and neck cancer	6.87e-05	0.00275	CbGeAlD
Methotrexate—Stomatitis—Docetaxel—head and neck cancer	6.86e-05	0.00108	CcSEcCtD
Methotrexate—Conjunctivitis—Docetaxel—head and neck cancer	6.84e-05	0.00108	CcSEcCtD
Methotrexate—Body temperature increased—Hydroxyurea—head and neck cancer	6.83e-05	0.00108	CcSEcCtD
Methotrexate—Leukopenia—Fluorouracil—head and neck cancer	6.82e-05	0.00108	CcSEcCtD
Methotrexate—Asthenia—Vinblastine—head and neck cancer	6.8e-05	0.00107	CcSEcCtD
Methotrexate—Hepatobiliary disease—Docetaxel—head and neck cancer	6.65e-05	0.00105	CcSEcCtD
Methotrexate—Epistaxis—Docetaxel—head and neck cancer	6.64e-05	0.00105	CcSEcCtD
Methotrexate—Convulsion—Fluorouracil—head and neck cancer	6.6e-05	0.00104	CcSEcCtD
Methotrexate—Agranulocytosis—Docetaxel—head and neck cancer	6.57e-05	0.00104	CcSEcCtD
Methotrexate—Chest pain—Fluorouracil—head and neck cancer	6.49e-05	0.00103	CcSEcCtD
Methotrexate—Myalgia—Fluorouracil—head and neck cancer	6.49e-05	0.00103	CcSEcCtD
Methotrexate—Diarrhoea—Vinblastine—head and neck cancer	6.48e-05	0.00102	CcSEcCtD
Methotrexate—Discomfort—Fluorouracil—head and neck cancer	6.41e-05	0.00101	CcSEcCtD
Methotrexate—Hypersensitivity—Hydroxyurea—head and neck cancer	6.36e-05	0.00101	CcSEcCtD
Methotrexate—Haemoglobin—Docetaxel—head and neck cancer	6.35e-05	0.001	CcSEcCtD
Methotrexate—Haemorrhage—Docetaxel—head and neck cancer	6.32e-05	0.000999	CcSEcCtD
Methotrexate—Hepatitis—Docetaxel—head and neck cancer	6.32e-05	0.000999	CcSEcCtD
Methotrexate—Confusional state—Fluorouracil—head and neck cancer	6.27e-05	0.000991	CcSEcCtD
Methotrexate—Pharyngitis—Docetaxel—head and neck cancer	6.27e-05	0.000991	CcSEcCtD
Methotrexate—Dizziness—Vinblastine—head and neck cancer	6.26e-05	0.000991	CcSEcCtD
Methotrexate—ALB—lymph node—head and neck cancer	6.25e-05	0.0025	CbGeAlD
Methotrexate—Urinary tract disorder—Docetaxel—head and neck cancer	6.24e-05	0.000986	CcSEcCtD
Methotrexate—Anaphylactic shock—Fluorouracil—head and neck cancer	6.22e-05	0.000983	CcSEcCtD
Methotrexate—Asthenia—Hydroxyurea—head and neck cancer	6.2e-05	0.00098	CcSEcCtD
Methotrexate—Urethral disorder—Docetaxel—head and neck cancer	6.19e-05	0.000979	CcSEcCtD
Methotrexate—Infection—Fluorouracil—head and neck cancer	6.18e-05	0.000977	CcSEcCtD
Methotrexate—Nervous system disorder—Fluorouracil—head and neck cancer	6.1e-05	0.000964	CcSEcCtD
Methotrexate—Thrombocytopenia—Fluorouracil—head and neck cancer	6.09e-05	0.000963	CcSEcCtD
Methotrexate—Visual impairment—Docetaxel—head and neck cancer	6.09e-05	0.000963	CcSEcCtD
Methotrexate—ABCC4—lymph node—head and neck cancer	6.05e-05	0.00242	CbGeAlD
Methotrexate—Vomiting—Vinblastine—head and neck cancer	6.02e-05	0.000952	CcSEcCtD
Methotrexate—Erythema multiforme—Docetaxel—head and neck cancer	5.97e-05	0.000944	CcSEcCtD
Methotrexate—Headache—Vinblastine—head and neck cancer	5.93e-05	0.000938	CcSEcCtD
Methotrexate—Anorexia—Fluorouracil—head and neck cancer	5.93e-05	0.000937	CcSEcCtD
Methotrexate—Diarrhoea—Hydroxyurea—head and neck cancer	5.91e-05	0.000935	CcSEcCtD
Methotrexate—Eye disorder—Docetaxel—head and neck cancer	5.9e-05	0.000933	CcSEcCtD
Methotrexate—Cardiac disorder—Docetaxel—head and neck cancer	5.86e-05	0.000927	CcSEcCtD
Methotrexate—ABCC2—lymph node—head and neck cancer	5.85e-05	0.00234	CbGeAlD
Methotrexate—Hypotension—Fluorouracil—head and neck cancer	5.81e-05	0.000919	CcSEcCtD
Methotrexate—Angiopathy—Docetaxel—head and neck cancer	5.73e-05	0.000906	CcSEcCtD
Methotrexate—Dizziness—Hydroxyurea—head and neck cancer	5.71e-05	0.000903	CcSEcCtD
Methotrexate—Immune system disorder—Docetaxel—head and neck cancer	5.71e-05	0.000902	CcSEcCtD
Methotrexate—Mediastinal disorder—Docetaxel—head and neck cancer	5.69e-05	0.0009	CcSEcCtD
Methotrexate—Chills—Docetaxel—head and neck cancer	5.67e-05	0.000896	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	5.66e-05	0.000896	CcSEcCtD
Methotrexate—Nausea—Vinblastine—head and neck cancer	5.63e-05	0.00089	CcSEcCtD
Methotrexate—Insomnia—Fluorouracil—head and neck cancer	5.62e-05	0.000889	CcSEcCtD
Methotrexate—Paraesthesia—Fluorouracil—head and neck cancer	5.58e-05	0.000883	CcSEcCtD
Methotrexate—Alopecia—Docetaxel—head and neck cancer	5.58e-05	0.000883	CcSEcCtD
Methotrexate—Dyspnoea—Fluorouracil—head and neck cancer	5.54e-05	0.000877	CcSEcCtD
Methotrexate—Mental disorder—Docetaxel—head and neck cancer	5.53e-05	0.000875	CcSEcCtD
Methotrexate—Somnolence—Fluorouracil—head and neck cancer	5.53e-05	0.000874	CcSEcCtD
Methotrexate—Malnutrition—Docetaxel—head and neck cancer	5.5e-05	0.00087	CcSEcCtD
Methotrexate—Erythema—Docetaxel—head and neck cancer	5.5e-05	0.00087	CcSEcCtD
Methotrexate—Vomiting—Hydroxyurea—head and neck cancer	5.49e-05	0.000869	CcSEcCtD
Methotrexate—Dyspepsia—Fluorouracil—head and neck cancer	5.47e-05	0.000865	CcSEcCtD
Methotrexate—Rash—Hydroxyurea—head and neck cancer	5.45e-05	0.000861	CcSEcCtD
Methotrexate—Dermatitis—Hydroxyurea—head and neck cancer	5.44e-05	0.00086	CcSEcCtD
Methotrexate—Headache—Hydroxyurea—head and neck cancer	5.41e-05	0.000856	CcSEcCtD
Methotrexate—Decreased appetite—Fluorouracil—head and neck cancer	5.4e-05	0.000855	CcSEcCtD
Methotrexate—Dysgeusia—Docetaxel—head and neck cancer	5.38e-05	0.000852	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Fluorouracil—head and neck cancer	5.37e-05	0.000849	CcSEcCtD
Methotrexate—Back pain—Docetaxel—head and neck cancer	5.32e-05	0.000841	CcSEcCtD
Methotrexate—Pain—Fluorouracil—head and neck cancer	5.32e-05	0.000841	CcSEcCtD
Methotrexate—ABCC1—lymph node—head and neck cancer	5.16e-05	0.00206	CbGeAlD
Methotrexate—Nausea—Hydroxyurea—head and neck cancer	5.13e-05	0.000811	CcSEcCtD
Methotrexate—Feeling abnormal—Fluorouracil—head and neck cancer	5.12e-05	0.00081	CcSEcCtD
Methotrexate—Anaemia—Docetaxel—head and neck cancer	5.08e-05	0.000804	CcSEcCtD
Methotrexate—Urticaria—Fluorouracil—head and neck cancer	4.94e-05	0.000781	CcSEcCtD
Methotrexate—Leukopenia—Docetaxel—head and neck cancer	4.92e-05	0.000778	CcSEcCtD
Methotrexate—Body temperature increased—Fluorouracil—head and neck cancer	4.92e-05	0.000777	CcSEcCtD
Methotrexate—ABCB1—epithelium—head and neck cancer	4.84e-05	0.00194	CbGeAlD
Methotrexate—Cough—Docetaxel—head and neck cancer	4.8e-05	0.000759	CcSEcCtD
Methotrexate—Convulsion—Docetaxel—head and neck cancer	4.76e-05	0.000753	CcSEcCtD
Methotrexate—Arthralgia—Docetaxel—head and neck cancer	4.68e-05	0.00074	CcSEcCtD
Methotrexate—Myalgia—Docetaxel—head and neck cancer	4.68e-05	0.00074	CcSEcCtD
Methotrexate—Chest pain—Docetaxel—head and neck cancer	4.68e-05	0.00074	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	4.65e-05	0.000735	CcSEcCtD
Methotrexate—Hypersensitivity—Fluorouracil—head and neck cancer	4.58e-05	0.000724	CcSEcCtD
Methotrexate—Confusional state—Docetaxel—head and neck cancer	4.52e-05	0.000716	CcSEcCtD
Methotrexate—Anaphylactic shock—Docetaxel—head and neck cancer	4.49e-05	0.00071	CcSEcCtD
Methotrexate—Infection—Docetaxel—head and neck cancer	4.46e-05	0.000705	CcSEcCtD
Methotrexate—Nervous system disorder—Docetaxel—head and neck cancer	4.4e-05	0.000696	CcSEcCtD
Methotrexate—Pruritus—Fluorouracil—head and neck cancer	4.4e-05	0.000696	CcSEcCtD
Methotrexate—Thrombocytopenia—Docetaxel—head and neck cancer	4.39e-05	0.000695	CcSEcCtD
Methotrexate—Skin disorder—Docetaxel—head and neck cancer	4.36e-05	0.000689	CcSEcCtD
Methotrexate—ABCB1—trachea—head and neck cancer	4.28e-05	0.00171	CbGeAlD
Methotrexate—Anorexia—Docetaxel—head and neck cancer	4.28e-05	0.000676	CcSEcCtD
Methotrexate—ABCG2—lymph node—head and neck cancer	4.27e-05	0.00171	CbGeAlD
Methotrexate—Diarrhoea—Fluorouracil—head and neck cancer	4.25e-05	0.000673	CcSEcCtD
Methotrexate—Hypotension—Docetaxel—head and neck cancer	4.19e-05	0.000663	CcSEcCtD
Methotrexate—Dizziness—Fluorouracil—head and neck cancer	4.11e-05	0.00065	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Docetaxel—head and neck cancer	4.09e-05	0.000647	CcSEcCtD
Methotrexate—Insomnia—Docetaxel—head and neck cancer	4.06e-05	0.000642	CcSEcCtD
Methotrexate—Paraesthesia—Docetaxel—head and neck cancer	4.03e-05	0.000637	CcSEcCtD
Methotrexate—Dyspnoea—Docetaxel—head and neck cancer	4e-05	0.000633	CcSEcCtD
Methotrexate—Somnolence—Docetaxel—head and neck cancer	3.99e-05	0.000631	CcSEcCtD
Methotrexate—Vomiting—Fluorouracil—head and neck cancer	3.95e-05	0.000625	CcSEcCtD
Methotrexate—Dyspepsia—Docetaxel—head and neck cancer	3.95e-05	0.000625	CcSEcCtD
Methotrexate—Rash—Fluorouracil—head and neck cancer	3.92e-05	0.00062	CcSEcCtD
Methotrexate—Dermatitis—Fluorouracil—head and neck cancer	3.92e-05	0.000619	CcSEcCtD
Methotrexate—Decreased appetite—Docetaxel—head and neck cancer	3.9e-05	0.000617	CcSEcCtD
Methotrexate—Headache—Fluorouracil—head and neck cancer	3.9e-05	0.000616	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Docetaxel—head and neck cancer	3.87e-05	0.000613	CcSEcCtD
Methotrexate—Fatigue—Docetaxel—head and neck cancer	3.87e-05	0.000612	CcSEcCtD
Methotrexate—Pain—Docetaxel—head and neck cancer	3.84e-05	0.000607	CcSEcCtD
Methotrexate—ABCB1—lymphoid tissue—head and neck cancer	3.73e-05	0.00149	CbGeAlD
Methotrexate—Feeling abnormal—Docetaxel—head and neck cancer	3.7e-05	0.000585	CcSEcCtD
Methotrexate—Nausea—Fluorouracil—head and neck cancer	3.69e-05	0.000584	CcSEcCtD
Methotrexate—Gastrointestinal pain—Docetaxel—head and neck cancer	3.67e-05	0.00058	CcSEcCtD
Methotrexate—Body temperature increased—Docetaxel—head and neck cancer	3.55e-05	0.000561	CcSEcCtD
Methotrexate—Abdominal pain—Docetaxel—head and neck cancer	3.55e-05	0.000561	CcSEcCtD
Methotrexate—ABCB1—thyroid gland—head and neck cancer	3.39e-05	0.00136	CbGeAlD
Methotrexate—Hypersensitivity—Docetaxel—head and neck cancer	3.31e-05	0.000523	CcSEcCtD
Methotrexate—Asthenia—Docetaxel—head and neck cancer	3.22e-05	0.000509	CcSEcCtD
Methotrexate—Pruritus—Docetaxel—head and neck cancer	3.17e-05	0.000502	CcSEcCtD
Methotrexate—Diarrhoea—Docetaxel—head and neck cancer	3.07e-05	0.000486	CcSEcCtD
Methotrexate—ABCB1—head—head and neck cancer	3.01e-05	0.0012	CbGeAlD
Methotrexate—Dizziness—Docetaxel—head and neck cancer	2.97e-05	0.000469	CcSEcCtD
Methotrexate—Vomiting—Docetaxel—head and neck cancer	2.85e-05	0.000451	CcSEcCtD
Methotrexate—Rash—Docetaxel—head and neck cancer	2.83e-05	0.000447	CcSEcCtD
Methotrexate—Dermatitis—Docetaxel—head and neck cancer	2.83e-05	0.000447	CcSEcCtD
Methotrexate—Headache—Docetaxel—head and neck cancer	2.81e-05	0.000445	CcSEcCtD
Methotrexate—Nausea—Docetaxel—head and neck cancer	2.67e-05	0.000422	CcSEcCtD
Methotrexate—ABCB1—lymph node—head and neck cancer	2.11e-05	0.000842	CbGeAlD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	8.61e-06	0.000224	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—TYMS—head and neck cancer	8.59e-06	0.000223	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NAT2—head and neck cancer	8.57e-06	0.000222	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—DPYD—head and neck cancer	8.54e-06	0.000222	CbGpPWpGaD
Methotrexate—PGD—Disease—PTEN—head and neck cancer	8.51e-06	0.000221	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	8.51e-06	0.000221	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GSTM1—head and neck cancer	8.5e-06	0.000221	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—VEGFA—head and neck cancer	8.47e-06	0.00022	CbGpPWpGaD
Methotrexate—AOX1—Disease—NOTCH1—head and neck cancer	8.47e-06	0.00022	CbGpPWpGaD
Methotrexate—FPGS—Disease—PIK3CA—head and neck cancer	8.42e-06	0.000219	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—STAT3—head and neck cancer	8.32e-06	0.000216	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MAPK3—head and neck cancer	8.31e-06	0.000216	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—PIK3CA—head and neck cancer	8.3e-06	0.000215	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTGS2—head and neck cancer	8.17e-06	0.000212	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	8.15e-06	0.000212	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GPX1—head and neck cancer	8.14e-06	0.000211	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—DPYD—head and neck cancer	8.11e-06	0.000211	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—MAPK3—head and neck cancer	8.11e-06	0.000211	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—YAP1—head and neck cancer	8.1e-06	0.00021	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—AKT1—head and neck cancer	8.09e-06	0.00021	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CYP1A1—head and neck cancer	8.05e-06	0.000209	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—MAPK3—head and neck cancer	8.02e-06	0.000208	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MAPK3—head and neck cancer	7.95e-06	0.000206	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MAPK1—head and neck cancer	7.9e-06	0.000205	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—TYMS—head and neck cancer	7.83e-06	0.000203	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	7.82e-06	0.000203	CbGpPWpGaD
Methotrexate—FPGS—Disease—HRAS—head and neck cancer	7.79e-06	0.000202	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PTEN—head and neck cancer	7.79e-06	0.000202	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.77e-06	0.000202	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GSTM1—head and neck cancer	7.74e-06	0.000201	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—MAPK1—head and neck cancer	7.71e-06	0.0002	CbGpPWpGaD
Methotrexate—DHFR—Disease—NOTCH1—head and neck cancer	7.7e-06	0.0002	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—YAP1—head and neck cancer	7.7e-06	0.0002	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—MAPK1—head and neck cancer	7.63e-06	0.000198	CbGpPWpGaD
Methotrexate—PGD—Disease—STAT3—head and neck cancer	7.61e-06	0.000198	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MAPK1—head and neck cancer	7.56e-06	0.000196	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—EGFR—head and neck cancer	7.56e-06	0.000196	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—DPYD—head and neck cancer	7.51e-06	0.000195	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	7.51e-06	0.000195	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IL2—head and neck cancer	7.43e-06	0.000193	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GSTM1—head and neck cancer	7.41e-06	0.000193	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GPX1—head and neck cancer	7.41e-06	0.000192	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CYP1A1—head and neck cancer	7.33e-06	0.000191	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	7.3e-06	0.00019	CbGpPWpGaD
Methotrexate—PGD—Disease—MAPK3—head and neck cancer	7.27e-06	0.000189	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MAPK3—head and neck cancer	7.25e-06	0.000188	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—YAP1—head and neck cancer	7.13e-06	0.000185	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTEN—head and neck cancer	7.12e-06	0.000185	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GPX1—head and neck cancer	7.1e-06	0.000184	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PIK3CA—head and neck cancer	7.05e-06	0.000183	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PIK3CA—head and neck cancer	7.05e-06	0.000183	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CYP1A1—head and neck cancer	7.03e-06	0.000183	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	6.93e-06	0.00018	CbGpPWpGaD
Methotrexate—PGD—Disease—MAPK1—head and neck cancer	6.92e-06	0.00018	CbGpPWpGaD
Methotrexate—PGD—Disease—EGFR—head and neck cancer	6.91e-06	0.00018	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MAPK1—head and neck cancer	6.9e-06	0.000179	CbGpPWpGaD
Methotrexate—FPGS—Disease—AKT1—head and neck cancer	6.88e-06	0.000179	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—TYMS—head and neck cancer	6.88e-06	0.000179	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GSTM1—head and neck cancer	6.8e-06	0.000177	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AKT1—head and neck cancer	6.78e-06	0.000176	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.77e-06	0.000176	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.76e-06	0.000176	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—head and neck cancer	6.63e-06	0.000172	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—PIK3CA—head and neck cancer	6.62e-06	0.000172	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PIK3CA—head and neck cancer	6.56e-06	0.00017	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IL2—head and neck cancer	6.53e-06	0.00017	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GPX1—head and neck cancer	6.51e-06	0.000169	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CYP1A1—head and neck cancer	6.45e-06	0.000167	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—head and neck cancer	6.44e-06	0.000167	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—head and neck cancer	6.4e-06	0.000166	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—head and neck cancer	6.32e-06	0.000164	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—head and neck cancer	6.29e-06	0.000163	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	6.26e-06	0.000163	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—TYMS—head and neck cancer	6.21e-06	0.000161	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GSTM1—head and neck cancer	6.14e-06	0.000159	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—HRAS—head and neck cancer	6.12e-06	0.000159	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.09e-06	0.000158	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HRAS—head and neck cancer	6.07e-06	0.000158	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	6.05e-06	0.000157	CbGpPWpGaD
Methotrexate—PGD—Disease—PIK3CA—head and neck cancer	6e-06	0.000156	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—MAPK3—head and neck cancer	5.98e-06	0.000155	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.9e-06	0.000153	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GPX1—head and neck cancer	5.88e-06	0.000153	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CYP1A1—head and neck cancer	5.82e-06	0.000151	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—head and neck cancer	5.79e-06	0.00015	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	5.78e-06	0.00015	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—head and neck cancer	5.76e-06	0.00015	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AKT1—head and neck cancer	5.76e-06	0.00015	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—head and neck cancer	5.72e-06	0.000149	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—MAPK1—head and neck cancer	5.69e-06	0.000148	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.61e-06	0.000146	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTEN—head and neck cancer	5.61e-06	0.000146	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	5.56e-06	0.000144	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—head and neck cancer	5.55e-06	0.000144	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	5.55e-06	0.000144	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CA—head and neck cancer	5.5e-06	0.000143	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTEN—head and neck cancer	5.48e-06	0.000142	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	5.46e-06	0.000142	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—head and neck cancer	5.41e-06	0.00014	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TYMS—head and neck cancer	5.41e-06	0.00014	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—head and neck cancer	5.39e-06	0.00014	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—head and neck cancer	5.36e-06	0.000139	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GSTM1—head and neck cancer	5.34e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.31e-06	0.000138	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.3e-06	0.000138	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NAT2—head and neck cancer	5.29e-06	0.000137	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—head and neck cancer	5.26e-06	0.000137	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	5.25e-06	0.000136	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	5.17e-06	0.000134	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GPX1—head and neck cancer	5.12e-06	0.000133	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP1A1—head and neck cancer	5.06e-06	0.000132	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.04e-06	0.000131	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CA—head and neck cancer	5.03e-06	0.000131	CbGpPWpGaD
Methotrexate—MTHFR—Disease—STAT3—head and neck cancer	5.02e-06	0.00013	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	4.99e-06	0.00013	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTEN—head and neck cancer	4.99e-06	0.00013	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CA—head and neck cancer	4.94e-06	0.000128	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	4.92e-06	0.000128	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	4.92e-06	0.000128	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—head and neck cancer	4.9e-06	0.000127	CbGpPWpGaD
Methotrexate—AOX1—Disease—STAT3—head and neck cancer	4.9e-06	0.000127	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TYMS—head and neck cancer	4.86e-06	0.000126	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GSTM1—head and neck cancer	4.81e-06	0.000125	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MAPK3—head and neck cancer	4.8e-06	0.000125	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—head and neck cancer	4.79e-06	0.000124	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.78e-06	0.000124	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—head and neck cancer	4.77e-06	0.000124	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTEN—head and neck cancer	4.7e-06	0.000122	CbGpPWpGaD
Methotrexate—AOX1—Disease—MAPK3—head and neck cancer	4.68e-06	0.000122	CbGpPWpGaD
Methotrexate—ALB—Metabolism—DPYD—head and neck cancer	4.63e-06	0.00012	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NAT2—head and neck cancer	4.63e-06	0.00012	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TYMS—head and neck cancer	4.62e-06	0.00012	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GPX1—head and neck cancer	4.6e-06	0.00012	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTEN—head and neck cancer	4.59e-06	0.000119	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTM1—head and neck cancer	4.57e-06	0.000119	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—head and neck cancer	4.57e-06	0.000119	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MAPK1—head and neck cancer	4.56e-06	0.000119	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—head and neck cancer	4.56e-06	0.000118	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP1A1—head and neck cancer	4.56e-06	0.000118	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—head and neck cancer	4.49e-06	0.000117	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—head and neck cancer	4.46e-06	0.000116	CbGpPWpGaD
Methotrexate—AOX1—Disease—MAPK1—head and neck cancer	4.46e-06	0.000116	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—head and neck cancer	4.46e-06	0.000116	CbGpPWpGaD
Methotrexate—ALB—Metabolism—YAP1—head and neck cancer	4.4e-06	0.000114	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GPX1—head and neck cancer	4.38e-06	0.000114	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—head and neck cancer	4.36e-06	0.000113	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOTCH1—head and neck cancer	4.36e-06	0.000113	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	4.33e-06	0.000113	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP1A1—head and neck cancer	4.33e-06	0.000112	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TYMS—head and neck cancer	4.28e-06	0.000111	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	4.27e-06	0.000111	CbGpPWpGaD
Methotrexate—DHFR—Disease—MAPK3—head and neck cancer	4.26e-06	0.000111	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTM1—head and neck cancer	4.23e-06	0.00011	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—head and neck cancer	4.18e-06	0.000109	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—head and neck cancer	4.18e-06	0.000108	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.16e-06	0.000108	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	4.13e-06	0.000107	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—head and neck cancer	4.11e-06	0.000107	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—DPYD—head and neck cancer	4.06e-06	0.000105	CbGpPWpGaD
Methotrexate—DHFR—Disease—MAPK1—head and neck cancer	4.05e-06	0.000105	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—head and neck cancer	4.05e-06	0.000105	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GPX1—head and neck cancer	4.05e-06	0.000105	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—head and neck cancer	4.03e-06	0.000105	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP1A1—head and neck cancer	4.01e-06	0.000104	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—head and neck cancer	3.96e-06	0.000103	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—head and neck cancer	3.87e-06	0.0001	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—YAP1—head and neck cancer	3.85e-06	0.0001	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—head and neck cancer	3.83e-06	9.96e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—head and neck cancer	3.8e-06	9.88e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.74e-06	9.73e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—head and neck cancer	3.66e-06	9.51e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—head and neck cancer	3.64e-06	9.47e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—head and neck cancer	3.58e-06	9.29e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.56e-06	9.24e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	3.54e-06	9.19e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—head and neck cancer	3.52e-06	9.14e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.48e-06	9.05e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—head and neck cancer	3.46e-06	8.98e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—head and neck cancer	3.36e-06	8.74e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—head and neck cancer	3.34e-06	8.68e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—head and neck cancer	3.32e-06	8.61e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.3e-06	8.58e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—head and neck cancer	3.26e-06	8.45e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—head and neck cancer	3.24e-06	8.41e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—head and neck cancer	3.24e-06	8.41e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—head and neck cancer	3.23e-06	8.4e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—head and neck cancer	3.16e-06	8.21e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—head and neck cancer	3.02e-06	7.84e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—head and neck cancer	3.01e-06	7.82e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—head and neck cancer	2.95e-06	7.65e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.88e-06	7.49e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—head and neck cancer	2.87e-06	7.47e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—head and neck cancer	2.86e-06	7.43e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—head and neck cancer	2.82e-06	7.33e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—head and neck cancer	2.71e-06	7.04e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—head and neck cancer	2.71e-06	7.04e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK3—head and neck cancer	2.7e-06	7.03e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—head and neck cancer	2.68e-06	6.97e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—head and neck cancer	2.65e-06	6.87e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TYMS—head and neck cancer	2.64e-06	6.86e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—head and neck cancer	2.63e-06	6.82e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTM1—head and neck cancer	2.61e-06	6.78e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—head and neck cancer	2.58e-06	6.69e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK1—head and neck cancer	2.57e-06	6.68e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—head and neck cancer	2.57e-06	6.68e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—head and neck cancer	2.52e-06	6.56e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GPX1—head and neck cancer	2.5e-06	6.49e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1A1—head and neck cancer	2.47e-06	6.43e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAPK3—head and neck cancer	2.41e-06	6.26e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—head and neck cancer	2.41e-06	6.25e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—head and neck cancer	2.39e-06	6.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—head and neck cancer	2.36e-06	6.14e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—head and neck cancer	2.36e-06	6.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TYMS—head and neck cancer	2.31e-06	6.01e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAPK1—head and neck cancer	2.29e-06	5.96e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—head and neck cancer	2.29e-06	5.96e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTM1—head and neck cancer	2.29e-06	5.94e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—head and neck cancer	2.25e-06	5.83e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—head and neck cancer	2.23e-06	5.8e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—head and neck cancer	2.19e-06	5.69e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GPX1—head and neck cancer	2.19e-06	5.69e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1A1—head and neck cancer	2.17e-06	5.63e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—head and neck cancer	2.16e-06	5.61e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—head and neck cancer	2.13e-06	5.53e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—head and neck cancer	2.1e-06	5.46e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—head and neck cancer	2.08e-06	5.4e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—head and neck cancer	2.07e-06	5.37e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.03e-06	5.28e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—head and neck cancer	1.99e-06	5.17e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—head and neck cancer	1.93e-06	5e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—head and neck cancer	1.85e-06	4.81e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—head and neck cancer	1.84e-06	4.78e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—head and neck cancer	1.82e-06	4.74e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—head and neck cancer	1.74e-06	4.52e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—head and neck cancer	1.67e-06	4.33e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—head and neck cancer	1.63e-06	4.22e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—head and neck cancer	1.58e-06	4.12e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—head and neck cancer	1.51e-06	3.93e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—head and neck cancer	1.47e-06	3.82e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—head and neck cancer	1.47e-06	3.81e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—head and neck cancer	1.36e-06	3.54e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—head and neck cancer	1.29e-06	3.36e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—head and neck cancer	1.29e-06	3.35e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—head and neck cancer	1.28e-06	3.33e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—head and neck cancer	1.2e-06	3.11e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—head and neck cancer	1.12e-06	2.92e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—head and neck cancer	9.05e-07	2.35e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—head and neck cancer	7.93e-07	2.06e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—head and neck cancer	7.4e-07	1.92e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—head and neck cancer	6.48e-07	1.68e-05	CbGpPWpGaD
